SeminarLiver cirrhosis
Introduction
Fibrosis describes encapsulation or replacement of injured tissue by a collagenous scar. Liver fibrosis results from the perpetuation of the normal wound-healing response, resulting in an abnormal continuation of fibrogenesis (connective tissue production and deposition). Fibrosis progresses at variable rates depending on the cause of liver disease, environmental factors, and host factors.1, 2, 3 Cirrhosis is an advanced stage of liver fibrosis that is accompanied by distortion of the hepatic vasculature. The resultant vascular distortion leads to shunting of the portal and arterial blood supply directly into the hepatic outflow (central veins), compromising exchange between hepatic sinusoids and the adjacent liver parenchyma—ie, hepatocytes. The hepatic sinusoids are lined by fenestrated endothelia that rest on a sheet of permeable connective tissue in the space of Disse, which also contains hepatic stellate cells and some mononuclear cells. The other side of the space of Disse is lined by hepatocytes that execute most of the known liver functions. In cirrhosis, the space of Disse is filled with scar tissue and endothelial fenestrations are lost, a process known as sinusoidal capillarisation.4 Histologically, cirrhosis is characterised by vascularised fibrotic septa that link portal tracts with each other and with central veins, resulting in hepatocyte islands surrounded by fibrotic septa and that are devoid of a central vein (figure 1). The major clinical consequences of cirrhosis are impaired hepatocyte (liver) function, an increased intrahepatic resistance (portal hypertension), and the development of hepatocellular carcinoma. The general circulatory abnormalities in cirrhosis (splanchnic vasodilation, vasoconstriction and hypoperfusion of kidneys, water and salt retention, increased cardiac output) are intimately linked to the hepatic vascular alterations and resulting portal hypertension. Cirrhosis and its associated vascular distortion are traditionally regarded as irreversible but recent data suggest that cirrhosis regression or even reversal is possible.5, 6
Section snippets
Epidemiology
The exact prevalence of cirrhosis worldwide is unknown. It was estimated at 0·15% or 400 000 in the USA,7 which accounted for more than 25 000 deaths and 373 000 hospital discharges in 1998.8 These numbers could be an underestimation, since we recognise the high prevalence of undiagnosed cirrhosis in both non-alcoholic steatohepatitis and hepatitis C. Similar numbers have been reported from Europe, and numbers are even higher in most Asian and African countries where chronic viral hepatitis B
Causes of cirrhosis
Causes of cirrhosis can usually be identified by the patient's history combined with serological and histological investigation (table 1).9, 10, 11, 12, 13, 14, 15, 16, 17 Alcoholic liver disease and hepatitis C are the most common causes in developed countries, whereas hepatitis B is the prevailing cause in most parts of Asia and sub-Saharan Africa. After the identification of hepatitis C virus in 1989 and of non-alcoholic steatohepatitis in obese patients with diabetes, the diagnosis of
Clinical presentation
Cirrhosis is often indolent, asymptomatic, and unsuspected until complications of liver disease are present. Many of these patients never come to clinical attention, and previously undiagnosed cirrhosis is often found at autopsy.23 Diagnosis of asymptomatic cirrhosis is usually made when incidental screening tests such as liver transaminases or radiological findings suggest liver disease, and patients undergo further assessment and liver biopsy (table 2).24, 25, 26, 27, 28 The recognition that
Imaging of cirrhosis
Ultrasonography, CT, and MRI are not sensitive enough to detect cirrhosis, and final diagnosis still relies on histology. However, their specificity is high if the cause is obvious, and imaging reveals an inhomogeous hepatic texture or surface, rarefied hepatic central vein, an enlarged caudate lobe, splenomegaly, or collateral veins.29, 30, 31, 32 However, other causes such as portal-vein thrombosis, parasitic diseases, or haematological cancers need to be excluded, and normal radiographic
Liver biopsy
Biopsy is considered the gold standard for diagnosis of cirrhosis, and sequential histological grading of inflammation and staging of fibrosis can assess risk of progression. Furthermore, biopsy is important for establishing the cause of cirrhosis in up to 20% of patients with previous unknown cause (table 3). However, biopsy is prone to considerable sampling variability in all liver diseases.43, 44, 45, 46 The staging of fibrosis in hepatitis C by use of the METAVIR system (which is simple and
Natural history and prognosis
The natural history of cirrhosis depends on both the cause and treatment of the underlying cause. Yearly rates of decompensation are 4% for viral hepatitis C and 10% for viral hepatitis B, and incidence of hepatocellular carcinoma is 2–7% per year. Decompensation in alcoholic cirrhosis with continued alcohol use is even more rapid and often associated with alcoholic hepatitis on a background of cirrhosis. Once decompensation has occurred in all types of liver disease, mortality without
Treatment and reversibility of cirrhosis
Elimination of the triggers leading to cirrhosis will probably delay progression to a higher CPT class and reduce the occurrence of hepatocellular carcinoma. Reports have shown that causal treatment could even reverse cirrhosis, although in some reports the effect of sampling variability cannot be excluded. Patients with alcoholic cirrhosis should not continue alcohol consumption because it drives hepatitis, which favours hepatic fibrogenesis and decompensation.54, 55, 56 Liver function often
Complications of cirrhosis
Major advances have been made in recent years to both prevent and treat the common complications of cirrhosis such as variceal bleeding, ascites, spontaneous bacterial peritonitis, and encephalopathy (table 5).72, 73, 74, 75, 76, 77, 78 However, bacterial infections are common, especially in decompensated cirrhosis, which exacerbates hepatic dysfunction, encephalopathy, and portal hypertension, and underlines the need for vigilance and rigorous antibiotic treatment. Enhanced bacterial
Hepatocellular carcinoma
Hepatocellular carcinoma is one of the commonest solid organ tumours worldwide, and cirrhosis is a major risk factor for progression, among others (panel 1).86, 87, 88 Its pathogenesis seems to arise from the development of regenerative nodules with small-cell dysplasia through to invasive hepatocellular carcinoma. Mortality of hepatocellular carcinoma associated with cirrhosis is rising in most developed countries, whereas mortality from cirrhosis not related to hepatocellular carcinoma is
Liver transplantation
The ultimate treatment for cirrhosis and end-stage liver disease is liver transplantation (panel 2). Most recent survival data from the United Network of Organ Sharing (UNOS) study91 indicates survival rates of 83%, 70%, and 61% at 1 year, 5 years, and 8 years, respectively. Survival is best in patients who are at home at the time of transplantation compared with those who are in the hospital or intensive-care unit. Advances in liver transplantation have been the improvement in
Molecular pathology of hepatic fibrosis and cirrhosis
The scar tissue in cirrhosis is composed of a complex assembly of different extracellular matrix molecules (ECM), consisting of: the fibril-forming interstitial collagens type I and III; basement membrane collagen type IV; non-collagenous glycoproteins such as fibronectin and laminin; elastic fibres; and glycosaminoglycans and proteoglycans, among others.94 Toxins, viruses, cholestasis, or hypoxia can trigger a wound healing reaction termed fibrogenesis—ie, the excess synthesis and deposition
Conclusions
Many advances have occurred in the clinical care of patients with cirrhosis and the complications of end-stage liver disease. Most of these treatments have focused on the underlying cause of cirrhosis and management of complications of portal hypertension. Research in the next 10 years could focus on the primary prevention and treatment of cirrhosis, such as the use of non-invasive tests to screen for earlier stages of fibrosis and to monitor antifibrotic drug effects, and pharmacological
References (154)
- et al.
Cirrhosis reversal: a duel between dogma and myth
J Hepatol
(2004) - et al.
Hypertrophic hepatic osteoarthropathy. Clinical roentgenologic, biochemical hormonal and cardiorespiratory studies, and review of the literature
Am J Med
(1979) - et al.
Cause and composition of foetor hepaticus
Lancet
(1994) - et al.
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Lancet
(1997) - et al.
Hyperglobulinaemia in liver disease
Lancet
(1973) - et al.
Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production
Blood
(2000) - et al.
Doppler in hepatic cirrhosis and chronic hepatitis
Semin Ultrasound CT MR
(2002) - et al.
Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent
Lancet
(1999) - et al.
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation
Hepatology
(2003) - et al.
Sampling variability of liver fibrosis in chronic hepatitis C
Hepatology
(2003)
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Am J Gastroenterol
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
Gastroenterology
Why do varices bleed?
Gastroenterol Clin North Am
Model for end-stage liver disease (MELD) and allocation of donor livers
Gastroenterology
Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score
J Hepatol
Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease
Am J Med
Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis
Gastroenterology
Management of cirrhosis due to chronic hepatitis C
J Hepatol
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
Gastroenterology
Histological outcome during long-term lamivudine therapy
Gastroenterology
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy
Gastroenterology
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
Gastroenterology
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
Gastroenterology
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients
Hepatology
Prognosis of histological cirrhosis in type 1 autoimmune hepatitis
Gastroenterology
Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
Gastroenterology
Prevention of variceal rebleeding
Lancet
Diagnosis and treatment of portal hypertension
Dig Liver Dis
Transjugular intrahepatic portosystemic shunt: current status
Gastroenterology
Hepatorenal syndrome
Lancet
Complications of cirrhosis III. Hepatic encephalopathy
J Hepatol
The intestinal flora and bacterial infection in cirrhosis
J Hepatol
Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation
Hepatology
Portopulmonary hypertension: an increasingly important complication of cirrhosis
Gastroenterology
Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study
Hepatology
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver
J Hepatol
Hepatocellular carcinoma
Lancet
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Gastroenterology
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
J Biol Chem
Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential
Gastroenterology
Transforming growth factor β and the liver
Hepatology
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease
Gastroenterology
Capillarization of the sinusoids
Gastroenterology
Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis
Arch Pathol Lab Med
Digestive diseases in the United States: epidemiology and impact. Publication number 94–1447
National Center for Health Statistics. Series 13
Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations
Klin Wochenschr
Cited by (1716)
Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders
2024, Advanced Drug Delivery ReviewsTherapeutic potential and mechanisms of Rifaximin in ameliorating iron overload-induced ferroptosis and liver fibrosis in vivo and in vitro
2024, Toxicology and Applied PharmacologyEtiological Spectrum of Cirrhosis in India: A Systematic Review and Meta-analysis
2024, Journal of Clinical and Experimental HepatologyMechanism and Effect of HNF4α Decrease in a Rat Model of Cirrhosis and Liver Failure
2024, Cellular and Molecular Gastroenterology and Hepatology